Secondary prophylaxis of an acute coronary syndrome during rituximab infusion
Med Clin (Barc). 2020 Jan 24;154(2):69-70.
doi: 10.1016/j.medcli.2019.04.007.
Epub 2019 Jun 6.
[Article in
English,
Spanish]
Affiliations
- 1 Departamento de Hematología, Institut Clínic de Malalties Hematològiques i Oncològiques (ICMHO), Hospital Clínic de Barcelona, Barcelona, España. Electronic address: atriguero@clinic.cat.
- 2 Departamento de Cardiología, Hospital Germans Trias i Pujol, Badalona, Barcelona, España.
- 3 Departamento de Hematología, Institut Català d'Oncologia, Hospital Germans Trias i Pujol, Institut de Recerca Josep Carreras, Universitat Autònoma de Barcelona, Badalona, Barcelona, España.
No abstract available
MeSH terms
-
Acute Coronary Syndrome / chemically induced
-
Acute Coronary Syndrome / prevention & control*
-
Aged
-
Antineoplastic Agents, Immunological / administration & dosage
-
Antineoplastic Agents, Immunological / adverse effects*
-
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Cardiovascular Agents / therapeutic use
-
Clopidogrel / therapeutic use
-
Cyclophosphamide / administration & dosage
-
Diltiazem / therapeutic use
-
Doxorubicin / administration & dosage
-
Female
-
Humans
-
Lymphoma, Follicular / drug therapy*
-
Lymphoma, Follicular / pathology
-
Platelet Aggregation Inhibitors / therapeutic use
-
Prednisone / administration & dosage
-
Rituximab / administration & dosage
-
Rituximab / adverse effects*
-
Secondary Prevention*
-
Vincristine / administration & dosage
Substances
-
Antineoplastic Agents, Immunological
-
Cardiovascular Agents
-
Platelet Aggregation Inhibitors
-
R-CHOP protocol
-
Rituximab
-
Vincristine
-
Doxorubicin
-
Cyclophosphamide
-
Clopidogrel
-
Diltiazem
-
Prednisone